14716-89-3

Basic information

• Product Name: (3-METHYLISOXAZOL-5-YL)METHANOL
• Synonyms: (3-METHYLISOXAZOL-5-YL)METHANOL;5-(Hydroxymethyl)-3-methylisoxazole 97%;5-(Hydroxymethyl)-3-methylisoxazole;(3-methylisoxazol-5-yl)methanol(SALTDATA: FREE);3-Methyl-5-isoxazoleMethanol, 97%;(3-Methylisoxazol-5-yl)methanol, (3-Methyl-1,2-oxazol-5-yl)methanol;5-(Hydroxymethyl)-3-methylisoxazole97%;(3-METHYLISOXAZOL-5-YL)METHANO
• CAS NO: 14716-89-3
• Molecular Formula: C₅H₇NO₂
• Molecular Weight: 113.12
• Mol File: 14716-89-3.mol

Chemical Properties

• Melting Point: 130 °C
• Boiling Point: 211.82°C (rough estimate)
• Flash Point: >110℃
• Appearance: /
• Density: 1.1521 g/L at 25℃
• Vapor Pressure: 0.019mmHg at 25°C
• Refractive Index: n/D1.4792
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 13.43±0.10(Predicted)
• CAS DataBase Reference: (3-METHYLISOXAZOL-5-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (3-METHYLISOXAZOL-5-YL)METHANOL(14716-89-3)
• EPA Substance Registry System: (3-METHYLISOXAZOL-5-YL)METHANOL(14716-89-3)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 14716-89-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3-METHYLISOXAZOL-5-YL)METHANOL is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
(3-METHYLISOXAZOL-5-YL)METHANOL is used as an intermediate in the production of agrochemicals, such as pesticides and herbicides, to improve agricultural productivity and crop protection.
Used in Organic Synthesis:
(3-METHYLISOXAZOL-5-YL)METHANOL is used as a starting material for the synthesis of a variety of heterocyclic compounds with biological activity, expanding the scope of organic chemistry research and applications.
Used in Research Applications:
(3-METHYLISOXAZOL-5-YL)METHANOL is used in various research settings as a chemical intermediate, enabling the exploration of new chemical reactions and the synthesis of novel compounds with potential applications in various fields.

InChI:InChI=1/C5H7NO2/c1-4-2-5(3-7)8-6-4/h2,7H,3H2,1H3

Upstream product

• 3511-32-8 5-methyl-3(2H)-furanone 
• 683-58-9 acetohydroximoyl chloride 
• 107-19-7 propargyl alcohol 
• 79-24-3 Nitroethane 
• 206055-88-1 3-(4-trifluoromethylphenyl)-5-hydroxymethylisoxazole 
• 271795-21-2 C₁₃H₁₁Cl₂N₃O₃ 
• 683-58-9 (Z)-N-hydroxyacetimidoyl chloride 
• 5780-37-0 (E)-acetaldoxime 
• 107-29-9 Acetaldehyde oxime 
• 4857-42-5 3-methyl-5-isoxazolecarboxylic acid 
• 63366-79-0 3-methylisoxazole-5-carboxylic acid ethyl ester 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 1004-96-2 3-methylisoxazole-5-carboxylic acid methyl ester 
• 215360-91-1 3-Methyl-5-trimethylsilanyloxymethyl-isoxazole 

Downstream Products

• 70753-36-5 3-methylisoxazole-5-carbaldehyde 
• 4857-42-5 3-methyl-5-isoxazolecarboxylic acid 
• 40340-41-8 5-chloromethyl-3-methylisoxazole 
• 36958-61-9 5-(bromomethyl)-3-methyl-1,2-oxazole 
• 331729-41-0 2-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzyl]isoindole-1,3-dione 
• 331729-40-9 5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzylamine 
• 331728-88-2 3-azido-5-{6-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy) benzylamino]purin-9-yl}-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide 
• 331727-55-0 CP-608039 
• 61858-76-2 (3-methyl-isoxazol-5-ylmethyl)-triphenyl-phosphonium; bromide 
• 1053720-00-5 3-Methyl-5-[2-((E)-2-methyl-3-{(2S,3S,4R,5S)-5-[(2S,3S)-3-((1R,2S)-1-methyl-2-trimethylsilanyloxy-propyl)-oxiranylmethyl]-3,4-bis-trimethylsilanyloxy-tetrahydro-pyran-2-yl}-propenyl)-4-(toluene-4-sulfonyl)-4,5-dihydro-oxazol-5-yl]-isoxazole 
• 96603-77-9 3-Methyl-5-propoxymethyl-isoxazole 
• 96603-78-0 5-Butoxymethyl-3-methyl-isoxazole 
• 55086-61-8 5-acetyl-3-methylisoxazole 
• 288318-31-0 2-(3-methylisoxazol-5-yl)acetonitrile 

Relevant articles and documents

CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR

Disclosed are compounds of Formula I or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Enantioselective Synthesis of the Cyclopiazonic Acid Family Using Sulfur Ylides

A convergent, nine-step (LLS), enantioselective synthesis of α-cyclopiazonic acid and related natural products is reported. The route features a) an enantioselective aziridination of an imine with a chiral sulfur ylide; b) a bioinspired (3+2)-cycloaddition of the aziridine onto an alkene; and c) installation of the acetyltetramic acid by an unprecedented tandem carbonylative lactamization/N?O cleavage of a bromoisoxazole.

Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity

The mineralocorticoid receptor (MR) is a nuclear hormone receptor involved in the regulation of body fluid and electrolyte homeostasis. In this study we explore selectivity triggers for a series of nonsteroidal MR antagonists to improve selectivity over other members of the oxosteroid receptor family. A biaryl sulfonamide compound was identified in a high-throughput screening (HTS) campaign. The compound bound to MR with pKi=6.6, but displayed poor selectivity over the glucocorticoid receptor (GR) and the progesterone receptor (PR). Following X-ray crystallography of MR in complex with the HTS hit, a compound library was designed that explored an induced-fit hypothesis that required movement of the Met852 side chain. An improvement in MR selectivity of 11- to 79-fold over PR and 23- to 234-fold over GR was obtained. Given the U-shaped binding conformation, macrocyclizations were explored, yielding a macrocycle that bound to MR with pKi=7.3. Two protein–ligand X-ray structures were determined, confirming the hypothesized binding mode for the designed compounds.

Isoxazole-Derived Amino Acids are Bromodomain-Binding Acetyl-Lysine Mimics: Incorporation into Histone H4 Peptides and Histone H3

A range of isoxazole-containing amino acids was synthesized that displaced acetyl-lysine-containing peptides from the BAZ2A, BRD4(1), and BRD9 bromodomains. Three of these amino acids were incorporated into a histone H4-mimicking peptide and their affinity for BRD4(1) was assessed. Affinities of the isoxazole-containing peptides are comparable to those of a hyperacetylated histone H4-mimicking cognate peptide, and demonstrated a dependence on the position at which the unnatural residue was incorporated. An isoxazole-based alkylating agent was developed to selectively alkylate cysteine residues in situ. Selective monoalkylation of a histone H4-mimicking peptide, containing a lysine to cysteine residue substitution (K12C), resulted in acetyl-lysine mimic incorporation, with high affinity for the BRD4 bromodomain. The same technology was used to alkylate a K18C mutant of histone H3.

SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS

The present disclosure relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Synthesis and biological evaluation of aryloxazole derivatives as antimitotic and vascular-disrupting agents for cancer therapy

A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.

Short synthesis of COX-2 inhibitor inotilone

An efficient three-step synthesis of COX-2 inhibitor inotilone from acetaldoxime is described. The structure of inotilone was elucidated via an aldol reaction between 5-methyl-3(2H)-furanone and 3,4-dihydroxybenzaldehyde. This approach describes a convenient pathway to 5-alkyl-3-furanones through isoxazole chemistry.

INTEGRASE INHIBITORS 3

The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.

Dipolarophilic behavior of the isoxazole ring in intramolecular nitrilimine cycloadditions

Upon base treatment with silver carbonate, isoxazolyl-substituted hydrazonoyl chlorides (4) and (12) undergo a sequential intra- intermolecular nitrilimine cycloaddition giving tetracyclic pyrazolydine derivatives (7) and (15).